AU2003208415B2 - Anti-CD20 antibodies and fusion proteins thereof and methods of use - Google Patents

Anti-CD20 antibodies and fusion proteins thereof and methods of use Download PDF

Info

Publication number
AU2003208415B2
AU2003208415B2 AU2003208415A AU2003208415A AU2003208415B2 AU 2003208415 B2 AU2003208415 B2 AU 2003208415B2 AU 2003208415 A AU2003208415 A AU 2003208415A AU 2003208415 A AU2003208415 A AU 2003208415A AU 2003208415 B2 AU2003208415 B2 AU 2003208415B2
Authority
AU
Australia
Prior art keywords
antibody
cell
antibodies
fragment
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003208415A
Other languages
English (en)
Other versions
AU2003208415A1 (en
Inventor
David M Goldenberg
Hans Hansen
Zhengxing Qu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of AU2003208415A1 publication Critical patent/AU2003208415A1/en
Application granted granted Critical
Publication of AU2003208415B2 publication Critical patent/AU2003208415B2/en
Priority to AU2009202613A priority Critical patent/AU2009202613B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
AU2003208415A 2002-02-14 2003-02-14 Anti-CD20 antibodies and fusion proteins thereof and methods of use Expired AU2003208415B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009202613A AU2009202613B2 (en) 2002-02-14 2009-06-29 Anti-CD20 antibodies and fusion proteins thereof and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35613202P 2002-02-14 2002-02-14
US60/356,132 2002-02-14
US41623202P 2002-10-07 2002-10-07
US60/416,232 2002-10-07
PCT/GB2003/000665 WO2003068821A2 (en) 2002-02-14 2003-02-14 Anti-cd20 antibodies and fusion proteins thereof and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009202613A Division AU2009202613B2 (en) 2002-02-14 2009-06-29 Anti-CD20 antibodies and fusion proteins thereof and methods of use

Publications (2)

Publication Number Publication Date
AU2003208415A1 AU2003208415A1 (en) 2003-09-04
AU2003208415B2 true AU2003208415B2 (en) 2009-05-28

Family

ID=27737521

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2003208415A Expired AU2003208415B2 (en) 2002-02-14 2003-02-14 Anti-CD20 antibodies and fusion proteins thereof and methods of use
AU2009202613A Expired AU2009202613B2 (en) 2002-02-14 2009-06-29 Anti-CD20 antibodies and fusion proteins thereof and methods of use
AU2011253536A Expired AU2011253536B2 (en) 2002-02-14 2011-11-18 Anti-CD20 antibodies and fusion proteins thereof and methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2009202613A Expired AU2009202613B2 (en) 2002-02-14 2009-06-29 Anti-CD20 antibodies and fusion proteins thereof and methods of use
AU2011253536A Expired AU2011253536B2 (en) 2002-02-14 2011-11-18 Anti-CD20 antibodies and fusion proteins thereof and methods of use

Country Status (10)

Country Link
US (4) US7151164B2 (https=)
EP (2) EP1519959B1 (https=)
JP (2) JP4498746B2 (https=)
KR (1) KR101033196B1 (https=)
CN (2) CN100522999C (https=)
AU (3) AU2003208415B2 (https=)
CA (1) CA2476166C (https=)
IL (2) IL204848A (https=)
RU (1) RU2004127458A (https=)
WO (1) WO2003068821A2 (https=)

Families Citing this family (289)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) * 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
WO2001003734A1 (en) * 1999-07-12 2001-01-18 Genentech, Inc. Blocking immune response to a foreign antigen using an antagonist which binds to cd20
CA2396793A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptรฌdeo tacis e br3 e empregos dos mesmos
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US7906118B2 (en) 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2011226858B2 (en) * 2002-12-16 2015-01-22 Genentech, Inc. Immunoglobulin variants and uses thereof
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CN1767860A (zh) * 2003-01-31 2006-05-03 ๅ…็–ซๅŒป็–—ๅ…ฌๅธ ๆ–ฝ็”จๆฒป็–—ๅ’Œ่ฏŠๆ–ญๅ‰‚็š„ๆ–นๆณ•ๅ’Œ็ป„ๅˆ็‰ฉ
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
JP4745242B2 (ja) * 2003-05-20 2011-08-10 ใ‚ขใƒ—ใƒฉใ‚คใƒ‰ ใƒขใƒฌใ‚ญใƒฅใƒฉใƒผ ใ‚จใƒœใƒชใƒฅใƒผใ‚ทใƒงใƒณ๏ผŒใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ๏ผฃ๏ฝ„๏ผ’๏ผ็ตๅˆๅˆ†ๅญ
EP1626992B1 (en) * 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeล„ z komรณrek B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US20050079184A1 (en) * 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Molรฉculas de uniรณn a antรญgeno con afinidad de uniรณn a receptores Fc y funciรณn efectora incrementadas
KR20060109494A (ko) * 2003-12-19 2006-10-20 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ์ž๊ฐ€๋ฉด์—ญ ์งˆํ™˜์˜ ์น˜๋ฃŒ์— ์žˆ์–ด์„œ ๏ฝƒ๏ฝ„20์˜ ๊ฒ€์ถœ
MXPA06006865A (es) * 2003-12-19 2006-08-23 Genentech Inc Deteccion de cd20 en rechazo de transplante.
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8003111B2 (en) * 2005-04-06 2011-08-23 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8034352B2 (en) 2005-04-06 2011-10-11 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc mรฉtodo de aumento do esgotamento de cรฉlulas b em mamรฌferos, mรฉtodo de aumento da eficรกcia do esgotamento de cรฉlulas b, mรฉtodo de tratamento de malignidade ou neoplasma de cรฉlulas b, mรฉtodo de alรฌvio de disfunรงรฃo autoimunolรณgica regulada por cรฉlulas b, mรฉtodo de esgotamento das cรฉlulas b e composiรงรฃo
AR049021A1 (es) * 2004-04-16 2006-06-21 Genentech Inc Tratamiento de trastornos con un anticuerpo que se une a cd20
JP2007536246A (ja) * 2004-05-05 2007-12-13 ใ‚ธใ‚งใƒใƒณใƒ†ใƒƒใ‚ฏใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใƒผใƒ†ใƒƒใƒ‰ ่‡ชๅทฑๅ…็–ซ็–พๆ‚ฃใฎไบˆ้˜ฒๆณ•
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc mรฉtodo para tratar cรกncer em um indivรฌduo
EP1751187A2 (en) * 2004-05-28 2007-02-14 Idexx Laboratories, Inc. Canine cd20 compositions
EP1765400A2 (en) * 2004-06-04 2007-03-28 Genentech, Inc. Method for treating lupus
TW201422238A (zh) * 2004-06-04 2014-06-16 Genentech Inc ๏ผฃ๏ฝ„๏ผ’๏ผๆŠ—้ซ”ๆ–ผๆฒป็™‚ๅคš็™ผๆ€ง็กฌๅŒ–็—‡ไน‹็”จ้€”ๅŠ็”จๆ–ผ่ฉฒ็”จ้€”ไน‹็‰ฉๅ“
WO2006005477A1 (en) * 2004-07-09 2006-01-19 Schering Ag Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
CN101027100A (zh) * 2004-07-22 2007-08-29 ๅฅๆณฐ็ง‘็”Ÿ็‰ฉๆŠ€ๆœฏๅ…ฌๅธ ๆฒป็–—ๅนฒ็‡ฅ็ปผๅˆๅพ็š„ๆ–นๆณ•
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONร“W Fc
KR20070057839A (ko) * 2004-08-19 2007-06-07 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ๋ณ€๊ฒฝ๋œ ์ดํŽ™ํ„ฐ ๊ธฐ๋Šฅ์„ ๊ฐ–๋Š” ํด๋ฆฌํŽฉํ‹ฐ๋“œ ๋ณ€์ด์ฒด
CA2580271A1 (en) * 2004-10-05 2006-04-20 Genentech, Inc. Method for treating vasculitis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc ู…ุฑูƒุจุงุช ุฃุฌุณุงู… ู…ุถุงุฏุฉ .
WO2006063150A2 (en) * 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
ZA200705459B (en) * 2005-01-13 2008-09-25 Genentech Inc Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP1865058B1 (en) 2005-03-31 2011-01-12 Biomedics Inc. Anti-cd-20 monoclonal antibody
US9623115B2 (en) 2005-04-06 2017-04-18 Ibc Pharmaceuticals, Inc. Dock-and-Lock (DNL) Complexes for Disease Therapy
EP1874824A4 (en) * 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
US9931413B2 (en) 2005-04-06 2018-04-03 Ibc Pharmaceuticals, Inc. Tetrameric cytokines with improved biological activity
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8158129B2 (en) 2005-04-06 2012-04-17 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
JP3989936B2 (ja) * 2005-04-07 2007-10-10 ้€ฒ ้ ˆๆฐธ ๆŠ—่…ซ็˜ๅ‰คๅŠใณๆ–ฐ่ฆ๏ฝ„๏ฝŽใ‚ขใƒผใ‚ผ
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ATE460672T1 (de) * 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
US20090208500A1 (en) * 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiรคล›no veลพu na cd37 i cd20
CA2619298C (en) * 2005-08-26 2017-07-04 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
JPWO2007102200A1 (ja) * 2006-03-07 2009-07-23 ๅ›ฝ็ซ‹ๅคงๅญฆๆณ•ไบบๅคง้˜ชๅคงๅญฆ ๆŠ—๏ฝƒ๏ฝ„๏ผ’๏ผใƒขใƒŽใ‚ฏใƒญใƒผใƒŠใƒซๆŠ—ไฝ“
US7727525B2 (en) * 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
BRPI0720565A2 (pt) * 2006-12-20 2013-09-17 Mmr Information Systems Inc anticorpos e mร‰todos para a sua preparaร‡รงo e seu uso
WO2008088658A2 (en) * 2007-01-17 2008-07-24 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
UA107557C2 (xx) 2007-07-06 2015-01-26 ะšะพะผะฟะพะทะธั†ั–ั ะฐะฝั‚ะธั‚ั–ะปะฐ ะพั„ะฐั‚ัƒะผัƒะผะฐะฑัƒ
KR20190140090A (ko) 2007-07-09 2019-12-18 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ํด๋ฆฌํŽฉํ‹ฐ๋“œ์˜ ์žฌ์กฐํ•ฉ ์ƒ์‚ฐ ๋™์•ˆ์˜ ๋””์ˆ ํ”ผ๋“œ ๊ฒฐํ•ฉ ํ™˜์›์˜ ๋ฐฉ์ง€
NZ583019A (en) * 2007-07-31 2011-05-27 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferรณn dirigido demuestra potentes actividades apoptรณticas y antitumorales
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
CN101889025B (zh) 2007-10-30 2013-11-13 ๅฅๆณฐ็ง‘็”Ÿ็‰ฉๆŠ€ๆœฏๅ…ฌๅธ ้€š่ฟ‡้˜ณ็ฆปๅญไบคๆขๅฑ‚ๆž่ฟ›่กŒ็š„ๆŠ—ไฝ“็บฏๅŒ–
EP2231183A2 (en) 2007-12-21 2010-09-29 Genentech, Inc. Therapy of rituximab-refractory rheumatoid arthritis patients
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
JP2011509675A (ja) * 2008-01-18 2011-03-31 ใƒกใƒ‡ใ‚ฃใƒŸใƒฅใƒผใƒณ๏ผŒใ‚จใƒซใ‚จใƒซใ‚ทใƒผ ้ƒจไฝ็‰น็•ฐ็š„ใ‚ณใƒณใ‚ธใƒฅใ‚ฒใƒผใ‚ทใƒงใƒณใฎใŸใ‚ใฎใ‚ทใ‚นใƒ†ใ‚คใƒณๆ“ไฝœๆŠ—ไฝ“
HRP20160855T1 (hr) * 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
JP5986745B2 (ja) 2008-07-15 2016-09-06 ใ‚ขใ‚ซใƒ‡ใƒŸใ‚ข ใ‚ทใƒ‹ใ‚ซ๏ผก๏ฝƒ๏ฝ๏ฝ„๏ฝ…๏ฝ๏ฝ‰๏ฝ ๏ผณ๏ฝ‰๏ฝŽ๏ฝ‰๏ฝƒ๏ฝ ๏ผฐ๏ฝ”๏ฝ†๏ฝ…ๆง˜ใฎใ‚ขใƒซใƒŸใƒ‹ใ‚ฆใƒ ใƒปใ‚ณใƒผใƒˆใƒปใ‚ฌใƒฉใ‚นใ‚นใƒฉใ‚คใƒ‰ไธŠใฎใ‚ฐใƒชใ‚ซใƒณใ‚ขใƒฌใ‚คใŠใ‚ˆใณ้–ข้€ฃใ™ใ‚‹ๆ–นๆณ•
AU2010222928B2 (en) * 2008-07-16 2012-11-29 Baylor Research Institute Antigen presenting cell targeted vaccines
JP6049163B2 (ja) * 2008-07-21 2016-12-21 ใ‚คใƒŸใƒฅใƒผใƒŽใƒกใƒ‡ใ‚ฃใ‚ฏใ‚นใ€ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰๏ผฉ๏ฝ๏ฝ๏ฝ•๏ฝŽ๏ฝ๏ฝ๏ฝ…๏ฝ„๏ฝ‰๏ฝƒ๏ฝ“๏ผŒ ๏ผฉ๏ฝŽ๏ฝƒ๏ผŽ ๆ”นๅ–„ใ•ใ‚ŒใŸๆฒป็™‚ไธŠใฎ็‰นๅพดใฎใŸใ‚ใฎๆŠ—ไฝ“ใฎๆง‹้€ ๅค‰็•ฐไฝ“
MX2011001506A (es) 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
EP2725037A1 (en) * 2008-09-04 2014-04-30 Vet Therapeutics, Inc. Monoclonal antibodies binding canine CD20
AU2014200771B2 (en) * 2008-09-04 2016-05-26 Vet Therapeutics, Inc. Monoclonal antibodies
BRPI0918978A2 (pt) 2008-09-10 2015-12-01 Genentech Inc composiรงรตes e mรฉtodos a prevenรงรฃo da degradaรงรฃo oxidativa das proteรญnas
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2010093480A2 (en) * 2009-02-16 2010-08-19 Biolex Therapeutics, Inc. Humanized anti-cd20 antibodies and methods of use
WO2010110838A2 (en) * 2009-03-25 2010-09-30 Vet Therapeutics Inc. Antibody constant domain regions and uses thereof
US20100247484A1 (en) * 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2435476A4 (en) 2009-05-27 2013-04-17 Synageva Biopharma Corp ANTIBODIES OBTAINED FROM BIRDS
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
CN104059955A (zh) 2009-08-11 2014-09-24 ๅผ—ยทๅ“ˆๅคซๆ›ผ-ๆ‹‰็ฝ—ๅˆ‡ๆœ‰้™ๅ…ฌๅธ ๅœจๆ— ่ฐทๆฐจ้…ฐ่ƒบ็š„็ป†่ƒžๅŸนๅ…ปๅŸบไธญ็š„่›‹็™ฝ่ดจ็”Ÿไบง
US8728730B2 (en) * 2009-09-03 2014-05-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
EP3009455A1 (en) 2009-09-16 2016-04-20 Immunomedics Inc. Class i anti-cea antibodies and uses thereof
EP2494050A4 (en) * 2009-10-30 2013-10-30 Merck Sharp & Dohme GRANULOCYTIC COLONY STIMULATING FACTOR MADE IN GLYCOENGINEERED PICHIA PASTORIS
WO2011057188A1 (en) * 2009-11-06 2011-05-12 Idexx Laboratories, Inc. Canine anti-cd20 antibodies
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinaciรณn de radio inmunoterapia y conjugados anticuerpo-fรกrmaco para mejorar la terapia contra el cรกncer
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
CA2786692A1 (en) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
TW201129384A (en) * 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
TW201129383A (en) * 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
BR112012022342A2 (pt) * 2010-03-04 2017-02-14 Vet Therapeutics Inc anticorpos monoclonais dirigidos a cd52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
JP5911813B2 (ja) * 2010-03-04 2016-04-27 ใƒ™ใƒƒใƒˆใƒปใ‚ปใƒฉใƒ”ใƒฅใƒผใƒ†ใ‚ฃใ‚ฏใ‚นใƒปใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰๏ผถ๏ฝ…๏ฝ” ๏ผด๏ฝˆ๏ฝ…๏ฝ’๏ฝ๏ฝ๏ฝ…๏ฝ•๏ฝ”๏ฝ‰๏ฝƒ๏ฝ“ ๏ผฉ๏ฝŽ๏ฝƒ๏ผŽ ๏ผฃ๏ฝ„๏ผ’๏ผใซๅฏพใ™ใ‚‹ใƒขใƒŽใ‚ฏใƒญใƒผใƒŠใƒซๆŠ—ไฝ“
CN102190728B (zh) * 2010-03-17 2014-07-02 ๆฐธๅ“ๅšๆตŽ(ไธŠๆตท)็”Ÿ็‰ฉๅŒป่ฏๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ ไธ€็งไบบๆบๅŒ–ๆŠ—cd20ๅ•ๅ…‹้š†ๆŠ—ไฝ“
CN104998269B (zh) 2010-03-22 2019-06-11 ๅผ—ยทๅ“ˆๅคซๆ›ผ-ๆ‹‰็ฝ—ๅˆ‡ๆœ‰้™ๅ…ฌๅธ ๅฏนไบŽ็จณๅฎšๅซๆœ‰่›‹็™ฝ่ดจ็š„ๅˆถๅ‰‚ๆœ‰็”จ็š„็ป„ๅˆ็‰ฉๅ’Œๆ–นๆณ•
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
KR20130060227A (ko) 2010-05-03 2013-06-07 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ๋‹จ๋ฐฑ์งˆ-ํ•จ์œ  ์ œ์ œ์˜ ์ ๋„ ๊ฐ์†Œ์— ์œ ์šฉํ•œ ์กฐ์„ฑ๋ฌผ ๋ฐ ๋ฐฉ๋ฒ•
CN103068378B (zh) 2010-05-10 2016-07-06 ไธญๅคฎ็ ”็ฉถ้™ข ๅ…ทๆœ‰ๆŠ—ๆตๆ„Ÿๆดปๆ€ง็š„ๆ‰Ž้‚ฃ็ฑณ้Ÿฆ่†ฆ้…ธ้…ฏๅŒ็ฑป็‰ฉๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•
KR102167261B1 (ko) 2010-06-18 2020-10-20 ์—‘์Šค๋ฐ”์ด์˜คํ…Œํฌ, ์ธํฌ. ๊ด€์ ˆ์—ผ ์น˜๋ฃŒ
SG186783A1 (en) 2010-06-24 2013-02-28 Genentech Inc Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
JP2013541501A (ja) 2010-08-03 2013-11-14 ใ‚จใƒ•ใƒปใƒ›ใƒ•ใƒžใƒณโˆ’ใƒฉใƒปใƒญใ‚ทใƒฅใƒปใ‚ขใ‚ฏใƒใ‚งใƒณใ‚ฒใ‚ผใƒซใ‚ทใƒฃใƒ•ใƒˆ ๆ…ขๆ€งใƒชใƒณใƒ‘ๆ€ง็™ฝ่ก€็—…๏ผˆ๏ฝƒ๏ฝŒ๏ฝŒ๏ผ‰ใฎใƒใ‚คใ‚ชใƒžใƒผใ‚ซใƒผ
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
TWI603738B (zh) 2010-11-08 2017-11-01 ๅปบๅ—ๅพทๅ…‹ๅ…ฌๅธ ็šฎไธ‹ๆŠ•ไบˆๆŠ—๏ผ๏ฝ‰๏ฝŒ๏ผ๏ผ–ๅ—้ซ”ๆŠ—้ซ”
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biolรณgicos e mรฉtodos para prever resposta aos antagonistas de cรฉlulas b
JP6130307B2 (ja) * 2011-03-17 2017-05-17 ใ‚ถ ใƒฆใƒ‹ใƒใƒผใ‚ทใƒ†ใ‚ฃ ใ‚ชใƒ– ใƒใƒผใƒŸใƒณใ‚ฌใƒ  ๅ†ๆŒ‡ๅ‘ๆ€งๅ…็–ซ็™‚ๆณ•
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP2014512184A (ja) * 2011-04-07 2014-05-22 ใƒกใƒขใƒชใ‚ขใƒซ ใ‚นใƒญใƒผใƒณโˆ’ใ‚ฑใ‚ฟใƒชใƒณใ‚ฐ ใ‚ญใƒฃใƒณใ‚ตใƒผ ใ‚ปใƒณใ‚ฟใƒผ ๆŠ—่…ซ็˜ๆŠ—ไฝ“โˆ’่…ซ็˜ๆŠ‘ๅˆถๅ› ๅญ่žๅˆใ‚ฟใƒณใƒ‘ใ‚ฏ่ณช็ต„ๆˆ็‰ฉใŠใ‚ˆใณใŒใ‚“ใฎๅ‡ฆ็ฝฎใฎใŸใ‚ใฎไฝฟ็”จๆ–นๆณ•
AU2012250924B2 (en) * 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
EP2729498A1 (en) 2011-07-06 2014-05-14 MorphoSys AG Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
CA2853637C (en) * 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
RU2648999C2 (ru) 2011-12-22 2018-03-29 ะ”ะถะตะฝะตะฝั‚ะตะบ, ะ˜ะฝะบ. ะกะฟะพัะพะฑั‹ ะฟะพะฒั‹ัˆะตะฝะธั ัั„ั„ะตะบั‚ะธะฒะฝะพัั‚ะธ ัั‚ะฐะฟะพะฒ ะพั‡ะธัั‚ะบะธ ะฑะตะปะบะฐ, ะฝะฐั…ะพะดัั‰ะธั…ัั ะฝะธะถะต ะฟะพ ะฟะพั‚ะพะบัƒ, ั ะธัะฟะพะปัŒะทะพะฒะฐะฝะธะตะผ ะผะตะผะฑั€ะฐะฝะฝะพะน ะธะพะฝะพะพะฑะผะตะฝะฝะพะน ั…ั€ะพะผะฐั‚ะพะณั€ะฐั„ะธะธ
US9447160B2 (en) * 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
KR20140119777A (ko) 2012-01-31 2014-10-10 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ํ•ญ-ig-e m1'' ํ•ญ์ฒด ๋ฐ ๊ทธ์˜ ์‚ฌ์šฉ ๋ฐฉ๋ฒ•
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013171287A1 (en) 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
NZ701915A (en) 2012-05-18 2016-11-25 Genentech Inc High-concentration monoclonal antibody formulations
CN102863531A (zh) * 2012-07-31 2013-01-09 ๅผ ็ˆฑๆ™– ไธ€็งๆŠ—cd20ๅ•ๅ…‹้š†ๆŠ—ไฝ“ๅŠๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅ’Œ็”จ้€”
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
WO2014031762A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma ุงู„ุฃุฌุณุงู… ุงู„ู…ุถุงุฏุฉ ู„ู…ุถุงุฏ cd3 ูˆุฌุฒูŠุฆุงุช ุฑุจุท ุงู„ุฃู†ุชูŠุฌูŠู† ุซู†ุงุฆูŠุฉ ุงู„ุชุญุฏูŠุฏ ุงู„ุชูŠ ุชุฑุจุท cd3 ูˆcd20 ูˆุงุณุชุฎุฏุงู…ุงุชู‡ุง
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljลกo uฤinkovitost in zmanjลกano toksiฤnost
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
CA2895284A1 (en) 2013-02-07 2014-08-14 Immunomedics, Inc. Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
CN105358177B (zh) 2013-04-17 2018-11-23 ่ฅฟๆ ผ่ฏบ่ฏๅ“ๆœ‰้™ๅ…ฌๅธ ๅŒ…ๅซtorๆฟ€้…ถๆŠ‘ๅˆถๅ‰‚ๅ’ŒimidๅŒ–ๅˆ็‰ฉ็š„่”ๅˆ็–—ๆณ•็”จไบŽๆฒป็–—็™Œ็—‡
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituรญda, composiรงรฃo farmacรชutica que os compreende, e kit
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc ไฝฟ็”จ๏ฝ”๏ฝ๏ฝ’ๆฟ€้…ถๆŠ‘ๅˆถๅŠ‘็ต„ๅˆ็™‚ๆณ•ไปฅๆฒป็™‚็™Œ็—‡ไน‹ๆ–นๆณ•
TW201534305A (zh) 2013-05-03 2015-09-16 Celgene Corp ไฝฟ็”จ็ต„ๅˆ็™‚ๆณ•ๆฒป็™‚็™Œ็—‡ไน‹ๆ–นๆณ•
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
CA2937123A1 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
TW201623331A (zh) * 2014-03-12 2016-07-01 ๆ™ฎ็พ…ๅธ็ด็”Ÿ็‰ฉ็ง‘ๅญธๅ…ฌๅธ ๆŠ—้ป‘่‰ฒ็ด ็˜ค็ดฐ่ƒž้ป่‘—ๅˆ†ๅญ๏ผˆ๏ฝ๏ฝƒ๏ฝ๏ฝ๏ผ‰ๆŠ—้ซ”้กžๅŠไฝฟ็”จๅฝผ็ญ‰ไน‹็›ธ้—œๆ–นๆณ•
TWI754319B (zh) 2014-03-19 2022-02-01 ็พŽๅ•†ๅ†็”Ÿๅ…ƒ้†ซ่—ฅๅ…ฌๅธ ็”จๆ–ผ่…ซ็˜คๆฒป็™‚ไน‹ๆ–นๆณ•ๅŠๆŠ—้ซ”็ต„ๆˆ็‰ฉ
CN103880957B (zh) * 2014-03-27 2016-01-20 ๅฎ‰ๅพฝๅคงๅญฆ ๆŠ—cd20ๆŠ—ๅŽŸ็š„ๆŠ—ไฝ“l1h1ๅŠๅ…ถๅบ”็”จ
WO2015148915A1 (en) 2014-03-27 2015-10-01 Academia Sinica Reactive labelling compounds and uses thereof
CN103880958B (zh) * 2014-03-27 2016-01-20 ๅฎ‰ๅพฝๅคงๅญฆ ๆŠ—cd20ๆŠ—ๅŽŸ็š„ๆŠ—ไฝ“l4h6ๅŠๅ…ถๅบ”็”จ
IL292311A (en) 2014-04-03 2022-06-01 Igm Biosciences Inc J-chain qualified
KR20170003720A (ko) 2014-05-27 2017-01-09 ์•„์นด๋ฐ๋ฏธ์•„ ์‹œ๋‹ˆ์นด ํ•ญ-๏ฝƒ๏ฝ„20 ๊ธ€๋ฆฌ์ฝ”ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 ์•„์นด๋ฐ๋ฏธ์•„ ์‹œ๋‹ˆ์นด ํ•ญ-๏ฝˆ๏ฝ…๏ฝ’2 ๊ธ€๋ฆฌ์ฝ”ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
CN106714829A (zh) 2014-05-28 2017-05-24 ไธญๅคฎ็ ”็ฉถ้™ข ๆŠ—TNFโ€‘ฮฑ้†ฃๆŠ—ไฝ“ๅŠๅ…ถ็”จ้€”
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
CA2960712A1 (en) 2014-09-08 2016-03-17 Academia Sinica Human inkt cell activation using glycolipids
CN117138060A (zh) 2014-10-07 2023-12-01 ๅ…็–ซๅŒป็–—ๅ…ฌๅธ ๆŠ—ไฝ“-่ฏ็‰ฉ็ผ€ๅˆ็‰ฉ็š„ๆ–ฐ่พ…ๅŠฉๅ‰‚็”จ้€”
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za leฤenje tumora upotrebom cd3xcd20 bispecifiฤnog antitela
CN110894240B (zh) * 2014-11-26 2022-04-15 ๆฃฎ็ง‘่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็ป“ๅˆcd3ๅ’Œ่‚ฟ็˜คๆŠ—ๅŽŸ็š„ๅผ‚ไบŒ่šไฝ“ๆŠ—ไฝ“
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
CN107531787B (zh) 2015-01-27 2022-01-18 ๆ‹‰ๆณ•ๅŒป็–—ๆœ‰้™ๅ…ฌๅธ ้ถๅ‘cd1d็š„ๅ•ๅŸŸๆŠ—ไฝ“
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
KR102357312B1 (ko) 2015-03-04 2022-02-03 ์•„์ด์ฅ์—  ๋ฐ”์ด์˜ค์‚ฌ์ด์–ธ์Šค ์ธ์ฝ”ํฌ๋ ˆ์ดํ‹ฐ๋“œ ๏ผฃ๏ฝ„20 ๊ฒฐํ•ฉ ๋ถ„์ž ๋ฐ ๊ทธ์˜ ์šฉ๋„
CN107406496A (zh) * 2015-03-10 2017-11-28 ็™พๆ—ถ็พŽๆ–ฝ่ดตๅฎๅ…ฌๅธ ๅฏ้€š่ฟ‡่ฝฌ่ฐทๆฐจ้…ฐ่ƒบ้…ถ็ผ€ๅˆ็š„ๆŠ—ไฝ“ๅ’Œ็”ฑๅ…ถๅˆถๅค‡็š„็ผ€ๅˆ็‰ฉ
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseรฑada.
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciaล‚o-sn-38 z linkerem cl2a
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
EP3824903A1 (en) 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECรFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y Mร‰TODOS DE USO
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
WO2017087843A1 (en) * 2015-11-20 2017-05-26 Immungene, Inc Methods of treating proliferative diseases using engineered antibody-interferon fusion molecules
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
CN115969970A (zh) 2016-02-10 2023-04-18 ๅ…็–ซๅŒป็–—ๅ…ฌๅธ Abcg2ๆŠ‘ๅˆถๅ‰‚ไธŽsacituzumab govitecan็š„็ป„ๅˆ
NZ744192A (en) * 2016-02-18 2019-11-29 Elanco Us Inc Chimeric canine anti-cd20 antibody
EP3423593A1 (en) 2016-03-02 2019-01-09 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
WO2017156192A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
JP7379795B2 (ja) 2016-04-27 2023-11-15 ใ‚คใƒŸใƒฅใƒผใƒŽใƒกใƒ‡ใ‚ฃใ‚ฏใ‚นใ€ใ‚คใƒณใ‚ณใƒผใƒใƒฌใ‚คใƒ†ใƒƒใƒ‰ ใƒใ‚งใƒƒใ‚ฏใƒใ‚คใƒณใƒˆ้˜ปๅฎณ่–ฌใซๅ†็™บ๏ผ่€ๆ€งใ‚’็คบใ™่…ซ็˜ใ‚’ๆฒป็™‚ใ™ใ‚‹ใŸใ‚ใฎๆŠ—๏ผด๏ฝ’๏ฝ๏ฝ๏ผ๏ผ’๏ผ๏ผณ๏ผฎ๏ผ๏ผ“๏ผ˜ๆŠ—ไฝ“่–ฌ็‰ฉ่ค‡ๅˆไฝ“ใฎๅŠนๆžœ
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3045592A1 (en) 2016-12-21 2018-06-28 Novartis Ag Antibody drug conjugates for ablating hematopoietic stem cells
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
CN107384963A (zh) * 2017-07-31 2017-11-24 ๅฑฑไธœๅ…ด็‘ž็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็งๅฏๆŽงๅž‹cd20ๅตŒๅˆๆŠ—ๅŽŸๅ—ไฝ“ไฟฎ้ฅฐt็ป†่ƒž็š„ๅˆถๅค‡ๆ–นๆณ•ๅŠๅ…ถๅบ”็”จ
EP3661555B1 (en) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20230132400A9 (en) * 2017-11-10 2023-04-27 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
KR102914621B1 (ko) 2018-01-03 2026-01-21 ํŒ”๋ ˆ์˜จ ํŒŒ๋งˆ์Šˆํ‹ฐ์นผ์Šค ์ธํฌ. ์žฌ์กฐํ•ฉ ์ธ๊ฐ„ ์‹œ์•Œ๋ฆฌ๋‹ค์ œ, ์‹œ์•Œ๋ฆฌ๋‹ค์ œ ์œตํ•ฉ ๋‹จ๋ฐฑ์งˆ, ๋ฐ ์ด๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ๋ฐฉ๋ฒ•
JP7332627B2 (ja) 2018-04-25 2023-08-23 ใƒ—ใƒญใƒกใƒ†ใ‚ฆใ‚น ใƒใ‚คใ‚ชใ‚ตใ‚คใ‚จใƒณใ‚ทใƒผใ‚บ๏ผŒใ‚คใƒณใ‚ฏ๏ผŽ ๆœ€้ฉๅŒ–ใ•ใ‚ŒใŸๆŠ—๏ฝ”๏ฝŒ๏ผ‘๏ฝๆŠ—ไฝ“
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
RS66543B1 (sr) 2018-08-31 2025-03-31 Regeneron Pharma Strategija doziranja koja ublaลพava sindrom oslobaฤ‘anja citokina za cd3/cd20 bispecifiฤna antitela
WO2020060406A1 (en) 2018-09-19 2020-03-26 Lava Therapeutics B.V. Novel bispecific antibodies for use in the treatment of hematological malignancies
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
RU2724469C2 (ru) * 2018-10-31 2020-06-23 ะ—ะฐะบั€ั‹ั‚ะพะต ะะบั†ะธะพะฝะตั€ะฝะพะต ะžะฑั‰ะตัั‚ะฒะพ "ะ‘ะธะพะบะฐะด" ะœะพะฝะพะบะปะพะฝะฐะปัŒะฝะพะต ะฐะฝั‚ะธั‚ะตะปะพ, ะบะพั‚ะพั€ะพะต ัะฟะตั†ะธั„ะธั‡ะตัะบะธ ัะฒัะทั‹ะฒะฐะตั‚ัั ั cd20
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020159918A2 (en) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
KR20210133237A (ko) 2019-02-27 2021-11-05 ์ œ๋„จํ…Œํฌ, ์ธํฌ. ํ•ญ-tigit ๋ฐ ํ•ญ-cd20 ๋˜๋Š” ํ•ญ-cd38 ํ•ญ์ฒด๋กœ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•œ ํˆฌ์•ฝ
BR112021019612A2 (pt) 2019-04-01 2021-11-30 Genentech Inc Formulaรงรตes, recipiente, artigo de fabricaรงรฃo, mรฉtodo para produzir a formulaรงรฃo e mรฉtodo para inibir a agregaรงรฃo de uma proteรญna presente em uma soluรงรฃo aquosa
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
US20220380742A1 (en) * 2019-07-03 2022-12-01 Palleon Pharmaceuticals Inc. Sialidase-cd20-antibody fusion proteins and methods of use thereof
JP2021059499A (ja) 2019-10-03 2021-04-15 ๆ—ฅๆœฌๅ…จ่–ฌๅทฅๆฅญๆ ชๅผไผš็คพ ใ‚คใƒŒ๏ฝƒ๏ฝ„๏ผ’๏ผใซๅฏพใ™ใ‚‹ใƒขใƒŽใ‚ฏใƒญใƒผใƒŠใƒซๆŠ—ไฝ“ๅˆใฏๆŠ—ไฝ“ใƒ•ใƒฉใ‚ฐใƒกใƒณใƒˆ
KR20220103721A (ko) 2019-10-24 2022-07-22 ํ”„๋กœ๋ฉ”ํ…Œ์šฐ์Šค ๋ฐ”์ด์˜ค์‚ฌ์ด์–ธ์‹œ์ฆˆ, ์ธํฌ. Tnf ์œ ์‚ฌ ๋ฆฌ๊ฐ„๋“œ 1a(tl1a)์— ๋Œ€ํ•œ ์ธ๊ฐ„ํ™” ํ•ญ์ฒด ๋ฐ ๊ทธ์˜ ์šฉ๋„
CN121197633A (zh) 2019-12-13 2025-12-26 ๆฏ”็‰นๆฏ”ๅพท็ง‘ๆœ‰้™่ดฃไปปๅ…ฌๅธ ็”จไบŽๅฐ†ๆฒป็–—ๅ‰‚้€’้€่‡ณ่ƒƒ่‚ ้“็š„ๅฏๆ‘„ๅ–่ฃ…็ฝฎ
CN116323667A (zh) 2020-07-08 2023-06-23 ๆ‹‰ๆณ•ๅŒป็–—่‚กไปฝๆœ‰้™ๅ…ฌๅธ ็ป“ๅˆPSMAๅ’Œฮณ-ฮดT็ป†่ƒžๅ—ไฝ“็š„ๆŠ—ไฝ“
CA3187245A1 (en) * 2020-08-17 2022-02-24 Sebastien Mercx Recombinant immunotoxin comprising a ribotoxin or rnase
CN112851810B (zh) * 2021-01-23 2021-09-07 ๅŒ—ไบฌ็ง‘่ทƒไธญๆฅท็”Ÿ็‰ฉๆŠ€ๆœฏๆœ‰้™ๅ…ฌๅธ Cd20ๆŠ—ไฝ“ๅŠๅ…ถๆฒป็–—็™Œ็—‡็š„ๅบ”็”จ
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
EP4385522A1 (en) 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Microtubule inhibitor-based antibody-drug conjugate
CN116120455B (zh) * 2021-08-23 2023-11-07 ไธœ่Žžๅธ‚ๆœ‹ๅฟ—็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็งๆŠ—ca15-3่›‹็™ฝ็š„้‡็ป„ๆŠ—ไฝ“
CN117881431A (zh) 2021-08-24 2024-04-12 ๆ˜†ๅฑฑๆ–ฐ่•ด่พพ็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็ง็”ฑๅฏๆ–ญ่ฃ‚่ฟžๆŽฅๅญๅถ่”็š„ๆŠ—ไฝ“ๅถ่”่ฏ็‰ฉ
CN118541392A (zh) 2021-09-28 2024-08-23 ๅ‡†ๆ˜Ÿ็”Ÿ็‰ฉๅŒป่ฏๆœ‰้™ๅ…ฌๅธ ๅคš็งๅฝขๅผ็š„ๅˆ†ๅญๅคๅˆ็‰ฉ
TW202321308A (zh) 2021-09-30 2023-06-01 ็พŽๅ•†ๅปบๅ—ๅพทๅ…‹ๅ…ฌๅธ ไฝฟ็”จๆŠ—๏ฝ”๏ฝ‰๏ฝ‡๏ฝ‰๏ฝ”ๆŠ—้ซ”ใ€ๆŠ—๏ฝƒ๏ฝ„๏ผ“๏ผ˜ๆŠ—้ซ”ๅŠ๏ฝ๏ฝ„โ€”๏ผ‘่ปธ็ตๅˆๆ‹ฎๆŠ—ๅŠ‘ๆฒป็™‚่ก€ๆถฒ็™Œ็—‡็š„ๆ–นๆณ•
CN118401258A (zh) 2021-12-09 2024-07-26 ๆ˜†ๅฑฑๆ–ฐ่•ด่พพ็”Ÿ็‰ฉ็ง‘ๆŠ€ๆœ‰้™ๅ…ฌๅธ ไธ€็งไบฒๅ’ŒๅŠ›ๆ”นๅ–„็š„ๆŠ—ไฝ“-่ฏ็‰ฉๅถ่”็‰ฉใ€ๅ…ถๅˆถๅค‡ๆ–นๆณ•ๅŠๅบ”็”จ
KR102709358B1 (ko) * 2022-02-08 2024-09-24 ์—ฐ์„ธ๋Œ€ํ•™๊ต ์‚ฐํ•™ํ˜‘๋ ฅ๋‹จ ์‹ ๊ทœ ์ด์ค‘ํƒ€๊ฒŸ ์œตํ•ฉํ•ญ์ฒด๋ฅผ ์œ ํšจ์„ฑ๋ถ„์œผ๋กœ ํฌํ•จํ•˜๋Š” ์•”์˜ ์˜ˆ๋ฐฉ ๋˜๋Š” ์น˜๋ฃŒ์šฉ ์กฐ์„ฑ๋ฌผ
IL318865A (en) 2022-08-10 2025-04-01 Kowa Co New drug complex
WO2024040149A2 (en) * 2022-08-17 2024-02-22 The Texas A&M University System Chicken-derived cd20 antibodies with potent b cell depletion activity
AU2024357712A1 (en) 2023-10-09 2026-04-23 Novartis Ag Extended dosing regimens for anti-cd20 antibodies in the treatment of multiple sclerosis
WO2025220804A1 (ko) * 2024-04-18 2025-10-23 ์ฃผ์‹ํšŒ์‚ฌ ํ๋กœ์…€ Cd5์— ๋Œ€ํ•œ ์‹ ๊ทœ ํ•ญ์ฒด ๋ฐ ์ด์˜ ์šฉ๋„

Citations (4)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2000044788A1 (en) * 1999-01-28 2000-08-03 Idec Pharmaceuticals Corporation Production of tetravalent antibodies
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas

Family Cites Families (38)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) 1975-02-04 1979-02-28 Searle & Co Immunological materials
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4734033A (en) * 1987-01-30 1988-03-29 Kv33 Corporation Flexible dental model articulator
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06501705A (ja) 1990-11-05 1994-02-24 ใƒ–ใƒชใ‚นใƒˆใƒซโˆ’ใƒžใ‚คใ‚ขใƒผใ‚บใ€€ใ‚นใ‚ฏใ‚คใƒ–ใ€€ใ‚ซใƒณใƒ‘ใƒ‹ใƒผ ๆŠ—โˆ’่…ซ็˜ๆŠ—ไฝ“ๅŠใณ็”Ÿ็‰ฉๅญฆ็š„ๆดปๆ€งๅ‰คใฎ็ต„ๅˆใ›ใซใ‚ˆใ‚‹็›ธไน—ๆฒป็™‚
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
US5798554A (en) 1995-02-24 1998-08-25 Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno MOS-technology power device integrated structure and manufacturing process thereof
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0888125B1 (en) 1996-03-20 2004-05-26 Immunomedics, Inc. GLYCOSYLATED IgG ANTIBODIES
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
CN100457914C (zh) 1999-04-15 2009-02-04 ่ทๅ…ฐๅ…‹้ฒๅกžๅฐ”ๅ…ฌๅธ ็”จ็ผ–็ ่…บ็—…ๆฏ’e1่›‹็™ฝ็š„ๅบๅˆ—ๅœจไบบไฝ“็ป†่ƒžไธญ็”Ÿไบง้‡็ป„่›‹็™ฝ
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
WO2000075333A1 (en) * 1999-06-07 2000-12-14 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CN101289511A (zh) * 2000-04-11 2008-10-22 ๆฐๅ—ๆŠ€ๆœฏๅ…ฌๅธ ๅคšไปทๆŠ—ไฝ“ๅŠๅ…ถๅบ”็”จ
AU2002241922B2 (en) * 2001-01-17 2007-10-25 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US6987044B2 (en) * 2003-09-25 2006-01-17 Promos Technologies Inc. Volatile memory structure and method for forming the same

Patent Citations (4)

* Cited by examiner, โ€  Cited by third party
Publication number Priority date Publication date Assignee Title
US5776456A (en) * 1992-11-13 1998-07-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
WO2000044788A1 (en) * 1999-01-28 2000-08-03 Idec Pharmaceuticals Corporation Production of tetravalent antibodies
US20020009427A1 (en) * 2000-03-24 2002-01-24 Wolin Maurice J. Methods of therapy for non-hodgkin's lymphoma
US20020009444A1 (en) * 2000-04-25 2002-01-24 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas

Non-Patent Citations (2)

* Cited by examiner, โ€  Cited by third party
Title
JOURNAL OF IMMUNOLOGY, vol. 162, no. 11, 1 June 1999, pages 6589-6595 *
ONCOLOGY no. SUPPL 8, October 1998 (1998-10), pages 63-76 *

Also Published As

Publication number Publication date
CN100522999C (zh) 2009-08-05
EP1519959A2 (en) 2005-04-06
US7151164B2 (en) 2006-12-19
CN1662557A (zh) 2005-08-31
CA2476166C (en) 2011-11-15
KR101033196B1 (ko) 2011-05-09
HK1074052A1 (en) 2005-10-28
IL204848A (en) 2012-10-31
JP4790831B2 (ja) 2011-10-12
JP4498746B2 (ja) 2010-07-07
EP2295468B1 (en) 2015-07-08
WO2003068821A3 (en) 2005-01-20
JP2006500904A (ja) 2006-01-12
EP1519959B1 (en) 2014-04-02
CN101914158A (zh) 2010-12-15
JP2009291197A (ja) 2009-12-17
KR20040086383A (ko) 2004-10-08
AU2011253536A1 (en) 2011-12-08
US20070020259A1 (en) 2007-01-25
IL204847A (en) 2012-10-31
EP2295468A1 (en) 2011-03-16
AU2009202613A1 (en) 2009-07-16
US20030219433A1 (en) 2003-11-27
US7435803B2 (en) 2008-10-14
RU2004127458A (ru) 2005-10-27
WO2003068821A2 (en) 2003-08-21
AU2011253536B2 (en) 2014-03-06
CA2476166A1 (en) 2003-08-21
US20120034185A1 (en) 2012-02-09
AU2003208415A1 (en) 2003-09-04
AU2009202613B2 (en) 2011-08-18
US20090155253A1 (en) 2009-06-18
US8057793B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
AU2003208415B2 (en) Anti-CD20 antibodies and fusion proteins thereof and methods of use
US9605071B2 (en) Anti-CD19 antibodies
US7462352B2 (en) Methods of treatng B-cell diseases using humanized anti-CD19 antibodies
US9184781B2 (en) Humanized antibodies and methods of humanizing antibodies
CA2752553A1 (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use
HK1074052B (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use
HK1149273A (en) Anti-cd20 antibodies and fusion proteins thereof and methods of use

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired